Avatrombopag interactions
Full monograph for AvatrombopagCheck it against another medicine
Medicines
37 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Asciminib | Majorsource also lists Moderate | Metabolism | Coadministration with asciminib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 2C9 isoenzyme. The mechanism is… | 1 sources — open the full entry |
| Carbamazepine | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Carfilzomib | Major | Synergy | Venous thromboembolic events, including deep vein thrombosis (DVT) and pulmonary embolism (PE), have occurred during treatment with carfilzomib, and concurrent… | 3 sources — open the full entry |
| Enzalutamide | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| FluconazolebaseOphthalmic | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inhibitors of CYP450 2C9 and 3A4 may increase the systemic exposure (AUC) to avatrombopag. This… | 6 sources — open the full entry |
| Fosphenytoin Sodium | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Imatinib Mesylate | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inhibitors of CYP450 2C9 and 3A4 may increase the systemic exposure (AUC) to avatrombopag. This… | 6 sources — open the full entry |
| Phenytoin Sodium | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Rifampicin | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Rifampicin + Isoniazid | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutol | Major | Metabolism | Concomitant use of avatrombopag with moderate to potent dual inducers of CYP450 2C9 and 3A4 may decrease the systemic exposure (AUC) of avatrombopag which may… | 4 sources — open the full entry |
| Apalutamide | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to… | 6 sources — open the full entry |
| Ceritinib | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Clarithromycin | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Elacestrant | Moderate | Absorption | Coadministration with elacestrant may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance… | 1 sources — open the full entry |
| Esomeprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Fenofibrate | Moderate | Metabolism | Coadministration with fenofibrate may increase the plasma concentrations and risk of adverse effects of drugs that are substrates of CYP450 2C19, 2A6, and 2C9… | 37 sources — open the full entry |
| Gemfibrozil | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Gilteritinib Fumarate | Moderate | Absorption | Coadministration with gilteritinib may increase the plasma concentrations and the risk of adverse effects of orally administered drugs that are substrates of… | 3 sources — open the full entry |
| Itraconazole | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Ketoconazole | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Ketoconazole + Zinc Pyrithione + Aleovera | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Lansoprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Lefamulin Acetate | Moderate | Metabolism | When administered orally, lefamulin may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. Based on… | 1 sources — open the full entry |
| Lopinavir + Ritonavir | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Mavacamten | Moderate | Metabolism | Coadministration with mavacamten may decrease the plasma concentrations of drugs that are primarily metabolized by CYP450 3A4, 2C9, and/or 2C19. The proposed… | 1 sources — open the full entry |
| Nelfinavir | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Nirmatrelvir + Ritonavir | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Phenobarbital | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to… | 6 sources — open the full entry |
| Posaconazole | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Primidone | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inducers may decrease the systemic exposure (AUC) of avatrombopag which may lead to… | 6 sources — open the full entry |
| Rabeprazole + Amoxicillin + Clarithromycin | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Selpercatinib | Moderate | Metabolism | Coadministration with selpercatinib may increase the plasma concentrations of drugs that are primarily metabolized by the CYP450 3A4 isoenzyme. The mechanism… | 2 sources — open the full entry |
| Sotorasib | Moderate | Distribution · Metabolism | Coadministration with sotorasib may alter the plasma concentrations of drugs that are substrates of the CYP450 3A4 isoenzyme as well as the P-glycoprotein… | 4 sources — open the full entry |
| Tucatinib | Moderate | Metabolism | Coadministration with tucatinib may increase the plasma concentrations of CYP450 3A4 substrates. The mechanism involves tucatinib-mediated inhibition of CYP450… | 1 sources — open the full entry |
| Vonoprazan + Amoxicillin + Clarithromycin | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
| Voriconazole | Moderate | Metabolism | Concomitant use of avatrombopag with strong CYP450 3A4/5 or CYP450 2C9 inhibitors may increase the systemic exposure (AUC) to avatrombopag. The increase in… | 4 sources — open the full entry |
Food & lifestyle
high-fat foods
ModerateAbsorption
Food reduces the variability in oral absorption and bioavailability of avatrombopag. According to the product labeling, avatrombopag peak plasma concentration (Cmax) and systemic exposure (AUC) were not affected when administered with either a low-fat (500 calories; 3 g fat, 15 g proteins, 108 g carbohydrates) or high-fat (918 calories; 59 g fat, 39 g proteins, 59 g carbohydrates) meal. However, the variability of avatrombopag exposure was reduced by 40% to 60% with food, and the time to reach Cmax was delayed by 0 to 2 hours relative to the fasted state.
What to do: To ensure consistent absorption and plasma drug levels, avatrombopag should be taken with food.
1 source
- "Product Information. Doptelet (avatrombopag)." Dova Pharmaceuticals (2018):
Conditions
Conditions in which Avatrombopag needs care, as documented in this source.
Kidney Failure, Chronic
ModerateThe effect of severe renal impairment (CrCl < 30 mL/min) including patients requiring hemodialysis on avatrombopag pharmacokinetics is unknown. Caution and monitoring is advised.
1 source
- "Product Information. Doptelet (avatrombopag)." Dova Pharmaceuticals (2018):
Thromboembolism
ModerateThromboembolic complications may result from increases in platelet counts with TPO receptor agonists such as avatrombopag, lusutrombopag, and eltrombopag. Consider the potential for increased risk of thromboembolism when administering these medications to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions (Factor V Leiden, Prothrombin 20210 A, Antithrombin deficiency or Protein C or S deficiency).
3 sources
- "Product Information. Promacta (eltrombopag)." GlaxoSmithKline (2008):
- "Product Information. Doptelet (avatrombopag)." Dova Pharmaceuticals (2018):
- "Product Information. Mulpleta (lusutrombopag)." Shionogi USA Inc (2018):